Information Provided By:
Fly News Breaks for October 14, 2016
PRTA
Oct 14, 2016 | 08:29 EDT
RBC Capital analyst Michael Yee blames the recent decline in Prtohena's stock on macro/political market uncertainties. The analyst thinks there is about a 70% chance that the data for the company's lead drug '001 will be positive next year, and he thinks that the stock could double to $125 if this occurs. He adds that the company has two other drugs, for Parkinsons' and inflammation, that could boost the stock in 2017-2019 and are not well-appreciated. Yee keeps a $95 price target and Outperform rating on the shares.
News For PRTA From the Last 2 Days
There are no results for your query PRTA
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.